Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K31/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220249518USE OF OUABAIN ANTAGONISTS TO INHIBIT VIRAL INFECTION
US 11.08.2022
Int.Class A61K 31/58
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
58containing heterocyclic rings, e.g. aldosterone, danazol, stanozolol, pancuronium, digitogenin
Appl.No 17725331 Applicant The U.S.A., as represented by the Secretary, Department of Health and Human Services Inventor Peter L. Collins

Embodiments of a method for inhibiting viral infection in a subject are provided herein. In some embodiments, the method comprises administration of a competitive antagonist of ouabain binding to ATP1A1 to inhibit respiratory syncytial virus infection in the subject.

2.20220249398Cannabinoid Formulation Containing Active Ingredients and Carrier for Transdermal Absorption to Treat Neuropathy
US 11.08.2022
Int.Class A61K 31/05
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
05Phenols
Appl.No 17704318 Applicant William Seidel Inventor William Seidel

The invention relates to a topical formulation in order to deliver an effective amount of broad-spectrum cannabidiol ointment, in conjunction with active ingredients, menthol and camphor. This invention is for the treatment of symptoms and improvement of sensation associated with peripheral neuropathy, particularly of the feet and hands. The present invention also provides for various topical application formulations.

3.20220249519COMPOSITIONS OF HYDROXY ACIDS WITH SALICYLIC ACID AND USES THEREFORE
US 11.08.2022
Int.Class A61K 31/616
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
60Salicylic acid; Derivatives thereof
612having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
616by carboxylic acids, e.g. acetylsalicylic acid
Appl.No 17666964 Applicant Able Derm LLC Inventor Frank DREHER

The present disclosure generally relates to topical compositions comprising a combination of at least one alpha-hydroxy acid (e.g., glycolic acid) combined with at least one beta-hydroxy acid (e.g., salicylic acid) in the presence of water-soluble polystyrenes or appropriate salts thereof. The present disclosure further provides methods of making and using such compositions.

4.20220249533COMPOSITIONS AND METHODS FOR BONE REPAIR AND BONE HEALTH
US 11.08.2022
Int.Class A61K 31/7076
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7076containing purines, e.g. adenosine, adenylic acid
Appl.No 17616499 Applicant DUKE UNIVERSITY Inventor Shyni Varghese

The present disclosure relates to polymer-based biomaterials for the systemic or localized delivery of osteoanabolic molecules, and their use in methods for treating and/or preventing bone degeneration and for promoting bone regeneration. In one aspect, the present invention provides a biomaterial comprising a polymer and a bioactive molecule binding moiety. In certain embodiments of the first aspect of the invention, the bioactive molecule binding moiety is an osteoanabolic molecule binding moiety.

5.202022103409Formulierung eines Nanotechnologie-basierten Liefersystems von Nano-Trägern zu Zellen des Immunsystems
DE 11.08.2022
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No 202022103409 Applicant Autade Kalyani Inventor

Eine Formulierung, die auf Nanotechnologie-Abgabe von Nanoträgern an Zellen des Immunsystems basiert, umfassend: eine erste Nano-Träger-Liganden-Zusammensetzung, die aus einem Kohlenhydrat und ähnlichen Resten besteht, die in der Lage sind, eine angeborene Immunantwort für ein Zellsystem zu stimulieren; einen zweiten Nano-Carrier-Liganden, der aus einem T-Zellen-Helferpeptid besteht; einen dritten Nano-Trägerliganden, der ein Gefahrensignal umfasst, das aus Endotoxinen, Hitzeschockproteinen, Nukleotiden, reaktiven Sauerstoffzwischenprodukten, Abbauprodukten der extrazellulären Matrix besteht; und wobei die Nano-Träger-Liganden-Zusammensetzung kovalent an den Kern gebunden ist, wobei die Nano-Träger-Liganden-Zusammensetzung eine Kohlenhydrateinheit umfasst.

6.WO/2022/166283CARBOHYDRATE COMPOSITION AS PHARMACEUTICAL COMPOSITION, AND USE THEREOF
WO 11.08.2022
Int.Class A61K 31/715
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
Appl.No PCT/CN2021/128375 Applicant MEDGAEA JAPAN CO., LTD. Inventor WU, Chang-Jer
The present invention provides a carbohydrate composition as a pharmaceutical composition, and use thereof. The carbohydrate composition comprises fucose, glucuronic acid, galactose, and arabinose. Based on the total weight of the carbohydrate composition, the content of the fucose is 45.5 wt% to 76 wt%, the content of the glucuronic acid is 11 wt% to 19 wt%, the content of the galactose is 4.5 wt% to 14.5 wt%, and the content of the arabinose is 5.5 wt% to 18 wt%. A pharmaceutical composition comprising the carbohydrate composition is provided. The carbohydrate composition and the pharmaceutical composition provided by the present invention can achieve the effects of taking care of the skin, inhibiting skin allergy, inhibiting skin inflammation, or alleviating atopic dermatitis.
7.WO/2022/166748COMPOUND FOR TREATING OR PREVENTING VIMENTIN-MEDIATED DISEASES
WO 11.08.2022
Int.Class C07D 251/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
251Heterocyclic compounds containing 1,3,5-triazine rings
02not condensed with other rings
12having three double bonds between ring members or between ring members and non-ring members
14with hydrogen or carbon atoms directly attached to at least one ring carbon atom
16to only one ring carbon atom
18with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
Appl.No PCT/CN2022/074275 Applicant LUODA BIOSCIENCES, INC. Inventor WU, Jianping
Provided in the present invention is a compound for treating or preventing vimentin-mediated diseases. The compound of the present invention is a s-triazine derivative, as shown in the following formula A, or a pharmaceutically acceptable carrier, prodrug, enantiomer, diastereomer, tautomer or solvate thereof, wherein R1, R2 and Z are as defined herein. The present invention further comprises the corresponding pharmaceutical use, and a method for treating and preventing diseases.
8.WO/2022/166793CDK INHIBITOR
WO 11.08.2022
Int.Class C07D 401/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
Appl.No PCT/CN2022/074491 Applicant SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. Inventor YAN, Xiaoxia
A compound serving as a selective CDK inhibitor, a pharmaceutical composition containing same, a useful intermediate for preparing the compound, and a use of the compound for preparing a drug for the treatment of cell proliferative diseases, such as cancer. The compound has the structure shown in formula (I-A).
9.WO/2022/166778A PHARMACEUTICAL COMPOSITION OF A CAPSID PROTEIN INHIBITOR AND PREPARATION METHOD THEREOF
WO 11.08.2022
Int.Class A61K 31/4985
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
Appl.No PCT/CN2022/074453 Applicant JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. Inventor GAO, Wei
A pharmaceutical composition of a capsid protein inhibitor and a preparation method thereof. Specifically, provided is a composition, comprising (S)-N5-(3,4-difluorophenyl)-6-methyl-N3-((R)-1,1,1-trifluoropropan-2-yl)-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazine-3,5(4H)-dicarboxamide or a pharmaceutically acceptable salt thereof and a hydroxypropylmethyl fiber. The composition has a good dissolution rate and superior stability.
10.WO/2022/167183BIO-BASED WOUND CLOSURE PREPARATION
WO 11.08.2022
Int.Class A61L 26/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
26Chemical aspects of, or use of materials for, liquid bandages
Appl.No PCT/EP2022/050552 Applicant BEIERSDORF AG Inventor OSORIO BLANCO, Ernesto Rafael
The present invention relates to a wound closure preparation made of nature-based raw materials, in particular to a sprayable bio-based wound closure preparation.